FEATURED COMPANIES
- Eisai Co., Ltd
- GW Pharmaceuticals Plc.
- H. Lundbeck A/S
- UCB Inc.
- MORE
Epilepsy is a chronic disease in which the patient’s brain activities become abnormal due to seizures. A seizure is an unexpected rush of electrical activity in the brain. A seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. The global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025.
Epilepsy can develop in both males and females of all races, ethnic backgrounds, and ages. It affects around 65 Million people globally. The United States has around 3.4 Million epilepsy patients; among them around 470 Thousand are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.
The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in the United States will also help in the growth of Epilepsy drug market during the forecast period as well.
This report titled “Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan), Drugs [(Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)], Treatment Drugs Generation (First, Second, Third), Company (Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.) & Forecast” provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.
By Country - United States is Dominating Global Epilepsy Drugs Market
The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China, and Japan. The United States is dominating the global epilepsy drugs market. Its share is expected to grow in the years to come due to the better healthcare support system, growing awareness and increasing per capita healthcare expenditure.
By Drugs - Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role
The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing a significant role in the epilepsy treatment. Epidiolex has a bright future ahead.
By Drugs Category - Second and Third Generation Plays the Significant Role
In this report, we have categorized the epilepsy drugs market into three generations; First Generation, Second Generation, Third Generation. It is anticipated that the second and third generation plays a significant role in the global epilepsy drugs market during the forecast period of 2019-2025.
Company Analysis
Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.
Countries covered in this report are:
- United States
- United Kingdom
- France
- Germany
- Italy
- Spain
- India
- China
- Japan
Epilepsy Drugs Category - By Generation:
- First Generation
- Second Generation
- Third Generation
Drugs covered in this report are:
- Vimpat (Lacosamide)
- Keppra (Levetiracetam)
- Sabril (Vigabatrin)
- Onfi (Clobazam)
- Fycompa
- Briviact (Brivaracetam)
- Epidiolex
- Cenobamate (YKP3089)
Companies covered in this report are:
- Eisai Co., Ltd
- UCB Inc.
- H. Lundbeck A/S
- GW Pharmaceuticals Plc.
FEATURED COMPANIES
- Eisai Co., Ltd
- GW Pharmaceuticals Plc.
- H. Lundbeck A/S
- UCB Inc.
- MORE
1. Introduction
1.1 Market Definition
1.2 Currency Conversion
2. Research Methodology
3. Executive Summary
4. Global Epilepsy Drugs Market (2013 - 2025)
5. Market Share - Global Epilepsy Drugs (2013 - 2025)
5.1 By Country
5.2 By Drugs Category
5.3 By Drugs
6. Country - Global Epilepsy Drugs Market Analysis (2013 - 2025)
6.1 United States
6.2 United Kingdom
6.3 France
6.4 Germany
6.5 Italy
6.6 Spain
6.7 India
6.8 China
6.9 Japan
7. By Drugs Category - Global Epilepsy Drugs Market Analysis (2013 - 2025)
7.1 First Generation
7.2 Second Generation
7.3 Third Generation
8. By Drugs - Global Epilepsy Drugs Market Analysis (2013 - 2025)
8.1 Vimpat (Lacosamide)
8.2 Keppra (Levetiracetam)
8.3 Sabril (Vigabatrin)
8.4 Onfi (Clobazam)
8.5 Fycompa
8.6 Briviact (Brivaracetam)
8.7 Epidiolex
8.8 Cenobamate (YKP3089)
9. Growth Drivers
9.1 Growing Awareness Programs Worldwide
9.2 Presence of Promising Pipeline for Epilepsy Therapeutics
10. Challenges
10.1 New Restrictions on Epilepsy Drug
10.2 High Cost of Antiepileptic Drugs
11. Eisai Co., Ltd.
11.1 Company Overview
11.2 Initiatives/Activities
11.2.1 Point 1
11.2.2 Point 2
11.2.3 Point 3
11.3 Financial Insight
12. UCB Inc.
12.1 Company Overview
12.2 Initiatives/Activities
12.2.1 Point 1
12.2.2 Point 2
12.2.3 Point 3
12.2.4 Point 4
12.3 Financial Insight
13. H. Lundbeck A/S
13.1 Company Overview
13.2 Initiatives/Activities
13.2.1 Point 1
13.2.2 Point 2
13.2.3 Point 3
13.3 Financial Insight
14. GW Pharmaceuticals Plc.
14.1 Company Overview
14.2 Initiatives/Activities
14.2.1 Point 1
14.2.2 Point 2
14.3 Financial Insight
List of Figures:
Figure 4 1: Global - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 4 2: Global - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 5 1: Global - Epilepsy Drugs Market Country Share (Percent), 2013 - 2018
Figure 5 2: Global - Forecast for Epilepsy Drugs Market Country Share (Percent), 2019 - 2025
Figure 5 3: Global - Epilepsy Drugs Category Market Share (Percent), 2013 - 2018
Figure 5 4: Global - Forecast for Epilepsy Drugs Category Market Share (Percent), 2019 - 2025
Figure 5 5: Global - Epilepsy Drugs Market Share (Percent), 2013 - 2018
Figure 5 6: Global - Forecast for Epilepsy Drugs Market Share (Percent), 2019 - 2025
Figure 6 1: United States - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 2: United States - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 3: United Kingdom - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 4: United Kingdom - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 5: France - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 6: France - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 7: Germany - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 8: Germany - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 9: Italy - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 10: Italy - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 11: Spain - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 12: Spain - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 13: India - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 14: India - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 15: China - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 16: China - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 6 17: Japan - Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 6 18: Japan - Forecast for Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 7 1: Global - First Generation Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 7 2: Global - Forecast for First Generation Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 7 3: Global - Second Generation Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 7 4: Global - Forecast for Second Generation Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 7 5: Global - Third Generation Epilepsy Drugs Market (Million US$), 2013 - 2018
Figure 7 6: Global - Forecast for Third Generation Epilepsy Drugs Market (Million US$), 2019 - 2025
Figure 8 1: Global Epilepsy Drugs Market - Vimpat (Lacosamide) Sales (Million US$), 2013 - 2018
Figure 8 2: Global Epilepsy Drugs Market - Forecast for Vimpat (Lacosamide) Sales (Million US$), 2019 - 2025
Figure 8 3: Global Epilepsy Drugs Market - Keppra (Levetiracetam) Sales (Million US$), 2013 - 2018
Figure 8 4: Global Epilepsy Drugs Market - Forecast for Keppra (Levetiracetam) Sales (Million US$), 2019 - 2025
Figure 8 5: Global Epilepsy Drugs Market - Sabril (Vigabatrin) Sales (Million US$), 2013 - 2018
Figure 8 6: Global Epilepsy Drugs Market - Forecast for Sabril (Vigabatrin) Sales (Million US$), 2019 - 2025
Figure 8 7: Global Epilepsy Drugs Market - Onfi (Clobazam) Sales (Million US$), 2013 - 2018
Figure 8 8: Global Epilepsy Drugs Market - Forecast for Onfi (Clobazam) Sales (Million US$), 2019 - 2025
Figure 8 9: Global Epilepsy Drugs Market - Fycompa Sales (Million US$), 2015 - 2018
Figure 8 10: Global Epilepsy Drugs Market - Forecast for Fycompa Sales (Million US$), 2019 - 2025
Figure 8 11: Global Epilepsy Drugs Market - Briviact (Brivaracetam) Sales (Million US$), 2016 - 2018
Figure 8 12: Global Epilepsy Drugs Market - Forecast for Briviact (Brivaracetam) Sales (Million US$), 2019 - 2025
Figure 8 13: Global Epilepsy Drugs Market - Present & Forecast for Epidiolex Sales (Million US$), 2018 - 2025
Figure 8 14: Global Epilepsy Drugs Market - Forecast for Cenobamate (YKP3089) Sales (Million US$), 2019 - 2025
Figure 9 1: Global - Epilepsy Therapeutics Studies (Number), November 2018
Figure 11 1: Eisai Co., Ltd - Global Sales (Million US$), 2013 - 2018
Figure 11 2: Eisai Co., Ltd - Forecast for Global Sales (Million US$), 2019 - 2025
Figure 12 1: UCB Inc. - Global Sales (Million US$), 2013 - 2018
Figure 12 2: UCB Inc. - Forecast for Global Sales (Million US$), 2019 - 2025
Figure 13 1: Lundbeck - Global Sales (Million US$), 2013 - 2018
Figure 13 2: Lundbeck - Forecast for Global Sales (Million US$), 2019 - 2025
Figure 14 1: GW Pharmaceuticals - Global Revenue (Million US$), 2013 - 2018
Figure 14 2: GW Pharmaceuticals - Forecast for Global Revenue (Million US$), 2019 - 2025
- Eisai Co., Ltd
- GW Pharmaceuticals Plc.
- H. Lundbeck A/S
- UCB Inc.
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
